Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.
about
COPD and its comorbidities: Impact, measurement and mechanismsClinical highlights: messages from MunichLarge-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohortsPredicting frequent COPD exacerbations using primary care dataThe effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.Predictors of mortality in elderly subjects with obstructive airway disease: the PILE scoreVariability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.Characteristics of Dutch and Swiss primary care COPD patients - baseline data of the ICE COLD ERIC study.A combined pulmonary function and emphysema score prognostic index for staging in Chronic Obstructive Pulmonary DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease.Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.Prediction of COPD-specific health-related quality of life in primary care COPD patients: a prospective cohort study.Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians.Adjusting for COPD severity in database research: developing and validating an algorithmPrediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease.Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets.External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations.Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease.Body mass index, airflow obstruction and dyspnea and body mass index, airflow obstruction, dyspnea scores, age and pack years-predictive properties of new multidimensional prognostic indices of chronic obstructive pulmonary disease in primary care.Change in health status in COPD: a seven-year follow-up cohort study.Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary diseaseManaging complex respiratory patients in the community: an evaluation of a pilot integrated respiratory care service.Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy.Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD.Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study.Update in chronic obstructive pulmonary disease 2009.Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine.Current controversies and future perspectives in chronic obstructive pulmonary disease.Multidimensional prognostic indices for use in COPD patient care. A systematic review.The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD.The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease.Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?Study design elements for rigorous quasi-experimental comparative effectiveness research.Moving towards patient-centered medicine for COPD management: multidimensional approaches versus phenotype-based medicine--a critical view.Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management.An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.
P2860
Q26786812-7167CD66-44B4-4978-A34E-F8ACC224FF6AQ28596781-5E8D80AE-6394-4AB9-94A7-DDE74BAD2E22Q30581769-D4E9BAAB-B50C-478F-90D8-A36CF5CBD842Q31028327-B4AB992C-2112-4F27-9B34-5F3DD017D2CAQ33649840-32461F9E-084F-4C1C-BA84-8B5AC7378743Q33683010-56198DA5-A179-4E14-A122-5F70163E1C19Q33796149-AA18DF7F-6040-459F-AB39-432635463211Q34089239-320E9A67-EACC-43E4-9D7E-82F3ED2CA288Q34400702-9EAB05FD-2937-4EE6-BF13-FF355B6C77FEQ34550471-6AB755CB-5768-495D-8CA6-D6426611D9F0Q35056993-89994698-50C7-4188-82B3-5075EB2E6026Q35108231-25D905BC-BC97-4D7D-B4FB-6D15AD4DB4CCQ35216272-5D1732A8-3FF7-4B9A-AF5A-D0BD6208F92DQ35225129-0F5A4A0F-3C3B-46FE-99A3-84DCB404653BQ35671695-619F8CB0-03B3-48A7-B008-1173607A19AFQ35826561-A295E86C-2A2B-477E-9B60-59C10D469384Q35981939-F235AFED-75B2-41B8-8ED3-4AB6C75E3E09Q36190129-EF9E767B-4362-43B0-90A1-C6946482F996Q36579746-30A16454-D43C-4570-AF12-EA85079CE44CQ36908069-AC31DF44-7531-41F7-ABF8-C4256FB619D4Q37177278-A575E420-3EBB-4EE8-8998-8C1875E05F47Q37232113-185AF6B2-D17C-411A-A006-2A9F478C7A5DQ37350573-6E9A7FB5-45CF-4E3C-9BE1-FB3D5EC17BBFQ37353892-3C1DBD91-5A3D-4491-8C47-E4D408AF05C2Q37419373-C89EE804-EBD0-46C3-84FC-16A3967D50EAQ37521929-292D2EA1-F062-41C8-B083-E26B6109CAC0Q37623969-2825BBAA-4360-452F-92B3-1EFB39C76231Q37628063-0442FA81-40CD-4767-82C0-477CBBCD67AFQ37676225-CFB4F756-360D-41C2-89EB-E16C49F0CB55Q37718404-D51B2DB0-1134-4691-B79B-7F40E46AAC04Q37822219-F57DB38D-5985-4599-8AF6-46ADDF539891Q37890759-A2EC3826-FE6D-4D93-A2EC-9FB94338D2EBQ37955912-A93E2078-A3F9-44AC-9D78-1FDCB8C8C46DQ38025596-CDF503F2-7E0D-4E5C-B577-9C7D858752C5Q38077797-B97A06E0-A5D7-43E5-9889-9386FAE2B6F7Q38116475-51C38351-5BA0-4444-B9AB-92B5EC9A9E33Q38162881-78FDA6A5-A8B0-4DD9-B0CC-DE7A03D3A441Q38219063-AE6650B9-4187-4979-B352-4457E89ED30BQ38282787-59364ADC-C9A9-44CC-A5D5-CEAF7DA06BEFQ38399184-26A4E2B4-F4C4-4925-8D4A-6FA98A90AD27
P2860
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Derivation and validation of a ...... onary disease: the DOSE Index.
@en
Derivation and validation of a ...... onary disease: the DOSE Index.
@nl
type
label
Derivation and validation of a ...... onary disease: the DOSE Index.
@en
Derivation and validation of a ...... onary disease: the DOSE Index.
@nl
prefLabel
Derivation and validation of a ...... onary disease: the DOSE Index.
@en
Derivation and validation of a ...... onary disease: the DOSE Index.
@nl
P2093
P2860
P50
P1476
Derivation and validation of a ...... monary disease: the DOSE Index
@en
P2093
Gavin C Donaldson
Jadwiga A Wedzicha
Kozui Kida
Maria Dickson-Spillmann
Rupert C Jones
P2860
P304
P356
10.1164/RCCM.200902-0271OC
P407
P577
2009-09-24T00:00:00Z